• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    6/13/24 8:07:12 AM ET
    $APYX
    $BNOX
    $BRTX
    $CARA
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APYX alert in real time by email

    Gainers

    • Longeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million.
    • JanOne (NASDAQ:JAN) stock rose 26.07% to $3.24. The company's market cap stands at $37.8 million.
    • Bionomics (NASDAQ:BNOX) shares increased by 21.62% to $0.85. The market value of their outstanding shares is at $9.0 million.
    • BioRestorative Therapies (NASDAQ:BRTX) shares rose 20.74% to $1.63. The company's market cap stands at $11.0 million.
    • Holdco Nuvo Group DG (NASDAQ:NUVO) stock rose 20.22% to $1.84. The company's market cap stands at $61.2 million.
    • Vivani Medical (NASDAQ:VANI) stock rose 15.9% to $1.89. The market value of their outstanding shares is at $103.8 million.

    Losers

    • Assure Hldgs (NASDAQ:IONM) stock fell 46.4% to $0.27 during Thursday's pre-market session. The market value of their outstanding shares is at $2.4 million. As per the press release, Q1 earnings came out 4 days ago.
    • Cara Therapeutics (NASDAQ:CARA) shares decreased by 31.19% to $0.47. The company's market cap stands at $25.5 million.
    • Apyx Medical (NASDAQ:APYX) shares declined by 20.01% to $1.24. The market value of their outstanding shares is at $42.9 million.
    • Petros Pharma (NASDAQ:PTPI) shares declined by 16.31% to $0.45. The market value of their outstanding shares is at $3.1 million.
    • Catheter Precision (AMEX:VTAK) shares fell 14.95% to $0.51. The company's market cap stands at $3.8 million.
    • Connect Biopharma Hldgs (NASDAQ:CNTB) stock declined by 8.48% to $1.62. The market value of their outstanding shares is at $89.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APYX
    $BNOX
    $BRTX
    $CARA

    CompanyDatePrice TargetRatingAnalyst
    Apyx Medical Corporation
    $APYX
    12/16/2025$6.00Buy
    Roth Capital
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    Apyx Medical Corporation
    $APYX
    11/14/2025Mkt Perform → Mkt Outperform
    Citizens JMP
    Apyx Medical Corporation
    $APYX
    11/12/2025$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    Connect Biopharma Holdings Limited
    $CNTB
    6/12/2025$7.00Buy
    H.C. Wainwright
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Apyx Medical Corporation
    $APYX
    10/17/2024Neutral
    BTIG Research
    More analyst ratings

    $APYX
    $BNOX
    $BRTX
    $CARA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $APYX
    $BNOX
    $BRTX
    $CARA
    SEC Filings

    View All

    Roth Capital initiated coverage on Apyx Medical with a new price target

    Roth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00

    12/16/25 8:46:26 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Connect Biopharma with a new price target

    Lake Street initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $9.00

    12/1/25 9:37:24 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apyx Medical upgraded by Citizens JMP

    Citizens JMP upgraded Apyx Medical from Mkt Perform to Mkt Outperform

    11/14/25 10:23:10 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Connect Biopharma Holdings Limited

    SCHEDULE 13G - Connect Biopharma Holdings Ltd (0001835268) (Subject)

    2/17/26 5:22:24 PM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.

    SCHEDULE 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    2/17/26 10:50:32 AM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/13/26 8:40:45 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

    MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic aging-related conditions, today announced that results of its Phase 2b clinical trial were published today in Cell Stem Cell, a Cell Press Journal. The Phase 2b results demonstrated that intravenous laromestrocel, a mesenchymal stem cell product, improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. The full publication is available on the Cell Stem Cell website here. Laromestrocel (LOMECEL-B®) is a proprietary, scalable, allogeneic

    2/25/26 11:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

    GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 202026566

    2/24/26 8:30:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    2/18/26 4:16:13 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Roman Shawn David exercised 12,000 shares at a strike of $1.80 (SEC Form 4)

    4 - Apyx Medical Corp (0000719135) (Issuer)

    1/29/26 5:21:08 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026

    CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81

    2/25/26 9:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

    MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Third Quarter 2025 Results Conference Call Details: Date: Wednesday, November 12, 2025Time: 4:30 p.m. ETDomestic: 1-888-506-0062International: 1-973-528-0011Access Code: 464585 The call will also b

    11/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $APYX
    $BNOX
    $BRTX
    $CARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Petros Pharmaceuticals Inc.

    SC 13G/A - Petros Pharmaceuticals, Inc. (0001815903) (Subject)

    11/14/24 5:17:37 PM ET
    $PTPI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care